SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors are strongly recommended for patients with T2DM and heart failure (HF), particularly those with reduced ejection fraction (HFrEF), to reduce HF hospitalizations and cardiovascular mortality [2].